je.st
news
Tag: medicine
Merck Congratulates Awardees of 2015 Nobel Prize in Physiology or Medicine for Discovery Leading to River Blindness Treatment
2015-10-05 23:15:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. Co-recipient Dr. William C. Campbell Conducted his Nobel Prize-winning Work at Merck Research Laboratories KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, proudly congratulates William C. Campbell, a retired scientist from Merck Research Laboratories, who was jointly named the 2015 Nobel Prize winner in Physiology or Medicine with Satoshi Omura for the discovery of avermectin, which led to Mercks development of Mectizan (ivermectin), a treatment for river blindness (also known as onchocerciasis) in Africa, Latin America and Yemen. Language: English Contact: MerckMedia:Lainie Keller, 908-236-5036orClaire Gillespie, 267-305-0932orInvestors:Terri Loxam, 908-740-1986orJustin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: to
leading
treatment
river
VIDEO: The big business of Indian medicine
2015-09-17 04:21:23| BBC News | Business | UK Edition
Ayurveda, a form of medicine based around herbs and massage, has been around for centuries, and is big business in India's southern state of Kerala.
Tags: business
video
big
medicine
Guidelines Issued on Use of Antimicrobials in Veterinary Medicine
2015-09-15 02:00:00| ThePigSite - Industry News
EU - The European Commission has published guidelines that aim to prevent the overuse and misuse of antibiotics by sharing best-practices in Member States.
Tags: medicine
issued
guidelines
veterinary
New England Journal of Medicine (NEJM) Publishes Pivotal Phase 3 Data...
2015-09-10 06:45:57| Biotech - Topix.net
Alexion Pharmaceuticals, Inc. announced today that data from the pivotal Phase 3 ARISE study evaluating the safety and efficacy of Kanumaa in children and adults with lysosomal acid lipase deficiency have been published in the September 10 issue of the New England Journal of Medicine . In the study, Kanuma met the primary endpoint of alanine aminotransferase normalization compared with placebo as well as six secondary endpoints.1 Kanuma is an innovative enzyme replacement therapy that has been approved by the European Commission for the treatment of patients of all ages with LAL-D, a genetic, chronic, and progressive ultra-rare metabolic disease in which infants, children and adults suffer multi-organ damage and premature death.
Tags: data
journal
medicine
england
Incyte Announces Global License Agreement With Jiangsu Hengrui Medicine For SHR-1210, An Investigational Anti-PD-1 Monoclonal Antibody
2015-09-02 08:04:11| drugdiscoveryonline News Articles
Incyte Corporation recently announced a global license and collaboration agreement with Jiangsu Hengrui Medicine Co., Ltd. for the development and commercialization of SHR-1210, an investigational anti-PD-1 monoclonal antibody
Tags: global
agreement
license
medicine
Sites : [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] next »